Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)(Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)) - 药物靶点：CD19 x CD22_在研适应症：费城染色体阳性急性淋巴细胞白血病，CD19阳性B细胞急性淋巴细胞白血病，残留肿瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名

anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

靶点

CD19 x CD22

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、CD22抑制剂(CD22抑制剂)、免疫细胞毒性

+ [1]

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

费城染色体阳性急性淋巴细胞白血病CD19阳性B细胞急性淋巴细胞白血病残留肿瘤

非在研适应症-

原研机构

上海市第一人民医院

在研机构

上海市第一人民医院

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

3

项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的临床试验

ChiCTR2100052247 / CompletedN/AIIT

Prognostic value of 18F-FDG PET/CT radiomics in patients with B-cell lymphoma treated with CD19/CD22 dual-target CAR-T

开始日期2021-10-26

申办/合作机构

苏州大学附属第一医院

NCT05523661 / Recruiting临床1期IIT

The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia

To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic complete remission was observed then a lymphocyte collection will be administrated to patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells

开始日期2021-03-01

申办/合作机构

上海市第一人民医院

NCT03919526 / Completed临床1期IIT

The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR)-T Cell Therapy for Subjects With Measurable Residual Disease(MRD)-Positive B Cell Acute Lymphoblastic Leukemia

To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.

开始日期2019-08-11

申办/合作机构

上海市第一人民医院

100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的专利（医药）

登录后查看更多信息

20

项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的文献（医药）

2024-06-01·JAMA Oncology

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Article

作者: Ruff, Christer Alexander ; Hensen, Luca ; Faul, Christoph ; Schneider, Dina ; Lengerke, Claudia ; Bethge, Wolfgang Andreas ; Phely, Laurent

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

2023-11-14·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].

Article

作者: Guan, H H ; Zhao, D F ; Hou, R F ; Yan, H ; Lin, Y H ; An, L L ; Tong, C R ; Wu, T ; Liu, S Y

目的： 观察靶向CD22的抗体奥加伊妥珠单抗两剂疗法对于多线治疗后特别是嵌合抗原受体T细胞（CAR-T细胞）治疗后复发/难治急性B淋巴细胞白血病（R/R B-ALL）的疗效。 方法： 回顾性分析了2020年3月至2022年9月在北京高博博仁医院血液科接受两剂CD22单抗治疗并评估了疗效的R/R B-ALL患者（包括成人和儿童）。所有患者治疗前均经流式细胞术检测证实表达CD22抗原（>80%白血病细胞表达CD22）。所用CD22单抗为注射用奥加伊妥珠单抗，剂型为1 mg/瓶。成人每剂1 mg，儿童每剂不超过1 mg，最大剂量0.85 mg/m(2)；每例患者用两剂，总剂量均小于标准剂量1.8 mg/m(2)。 结果： 共纳入21例R/R B-ALL患者，5例儿童（<18岁）和16例成人。17例患者骨髓/外周血白血病细胞比例为5.0%~99.0%或伴有髓外病变，4例仅骨髓微小残留病（MRD）阳性。14例患者接受过CD19和CD22 CAR-T细胞治疗，4例接受过CD19 CAR-T细胞治疗，3例接受过CD3/CD19双特异性抗体治疗。11例为异基因造血干细胞移植后患者。经CD22单抗治疗后，14例（66.7%）患者获得完全缓解（CR，其中1例为MRD阳性CR），4例仅有骨髓MRD阳性者均转为MRD阴性。6例CD22 CAR-T细胞治疗失败者中，4例经随后的CD22单抗治疗达到CR。7例（33.3%）患者治疗无效。5例（23.8%）患者在抗体治疗过程中发生Ⅰ~Ⅲ级肝毒性，1例无效患儿在挽救性移植过程中发生肝静脉闭塞病（HVOD），经治疗后痊愈。 结论： 对于多线治疗（包括移植及CD19/CD22 CAR-T细胞）后的R/R B-ALL患者，两剂CD22抗体方案疗效好、费用低，肝毒性和HVOD发生率低。.

2023-10-01·Cancer research and treatment

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.

作者: Zou, Rui ; Jin, Zhengming ; Xia, Fan ; Kang, Liqing ; Wang, Peng ; Yu, Lei ; Liu, Hailing ; Wu, Depei ; Zhou, Xiao ; Qu, Changju

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton's tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.

100 项与 Anti-CD19/CD22 CAR-T cells(Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
费城染色体阳性急性淋巴细胞白血病	临床1期	中国	上海市第一人民医院	2021-03-01
CD19阳性B细胞急性淋巴细胞白血病	临床1期	中国	上海市第一人民医院	2019-08-11
残留肿瘤	临床1期	中国	上海市第一人民医院	2019-08-11